24/7 Market News Snapshot 23 October, 2025 – N2OFF, Inc. Common Stock (NASDAQ:NITO)
DENVER, Colo., 23 October, 2025 (www.247marketnews.com) – (NASDAQ:NITO) are discussed in this article.
N2OFF, Inc. (NASDAQ:NITO), a leader in the cleantech sector focused on solar energy, is experiencing a notable surge in stock value, trading at $4.654 in pre-market sessions, representing an impressive 21.51% increase from the previous close of $3.830. This uptick has generated significant trading volume, reaching 2.21 million shares, indicating heightened investor interest and confidence in the company’s growth trajectory.
The company’s optimism is fueled further by its recent strategic merger with MitoCareX Bio Ltd., an innovative biotech firm dedicated to developing advanced cancer therapeutics. This critical merger not only diversifies N2OFF’s offerings but also strengthens its growth strategy by integrating cutting-edge biopharmaceutical technologies into its portfolio. MitoCareX is recognized for its progress in drug discovery, focusing on the mitochondrial SLC25 protein family, which plays a crucial role in treating challenging cancers.
At the heart of MitoCareX’s approach is MITOLINE™, a proprietary algorithm leveraging 3D comparative modeling to identify potential anti-cancer treatments. This merger positions N2OFF to seize opportunities in a burgeoning market projected to reach $378.62 billion by 2032, marking a pivotal moment in the company’s evolution.
Amitay Weiss, Chairman of the Board, highlighted the potential of this collaboration, emphasizing that combining MitoCareX’s technology with N2OFF’s sustainable vision can yield significant advancements in health solutions and deliver shareholder value.
Post-acquisition, MitoCareX has become a wholly-owned subsidiary, with N2OFF committed to providing the necessary financial backing for ongoing projects during the crucial early years of this integration. This strategic alignment not only enhances N2OFF’s footprint in cleantech but also signals a robust integration of health innovation and sustainability initiatives, paving the way for a dynamic future.
Related news for (NITO)
- N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
- MoBot’s Stock Market Highlights – 10/07/25 01:00 PM
- SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
- N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer